Skip to main content

Lytgobi Side Effects

Generic name: futibatinib

Medically reviewed by Drugs.com. Last updated on Jun 18, 2023.

Note: This document contains side effect information about futibatinib. Some dosage forms listed on this page may not apply to the brand name Lytgobi.

Applies to futibatinib: oral tablet.

Serious side effects of Lytgobi

Along with its needed effects, futibatinib (the active ingredient contained in Lytgobi) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking futibatinib:

More common

Less common

Other side effects of Lytgobi

Some side effects of futibatinib may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For Healthcare Professionals

Applies to futibatinib: oral tablet.

Dermatologic

Very common (10% or more): Alopecia (34%), dry skin (29%), nail toxicity (47%), palmar-plantar erythrodysesthesia syndrome (21%)[Ref]

Gastrointestinal

Very common (10% or more): Abdominal pain (30%), constipation (39%), diarrhea (39%), dry mouth (35%), nausea (24%), stomatitis (30%), vomiting (20%)[Ref]

General

-The most common adverse reactions (20% or greater) were nail toxicity, musculoskeletal pain, constipation, diarrhea, fatigue, dry mouth, alopecia, stomatitis, abdominal pain, dry skin, arthralgia, dysgeusia, dry eye, nausea, decreased appetite, urinary tract infection, palmar-plantar erythrodysesthesia syndrome, and vomiting.

-Serious adverse reactions were reported in 39% of patients. Serious adverse reactions that occurred in 2% or more patients were pyrexia (3.9%), gastrointestinal hemorrhage (3.9%), ascites (2.9%), musculoskeletal pain (2.9%), and bile duct obstruction (2.9%).

-Permanent discontinuation due to an adverse reaction was reported in 4.9% of patients. Adverse reactions leading to discontinuation included esophagitis, oral dysesthesia, bile duct obstruction, dizziness, and anemia.

-The most common laboratory abnormalities (20% or greater) were increased phosphate, increased creatinine, decreased hemoglobin, increased glucose, increased calcium, decreased sodium, decreased phosphate, increased alanine aminotransferase, increased alkaline phosphatase, decreased lymphocyte, increased aspartate aminotransferase, decreased platelets, increased activated partial thromboplastin time, decreased leukocytes, decreased albumin, decreased neutrophils, increased creatine kinase, increased bilirubin, decreased glucose, increased prothrombin international normalized ratio, and decreased potassium.[Ref]

Metabolic

Very common (10% or more): Decreased appetite (23%)[Ref]

Musculoskeletal

Very common (10% or more): Arthralgia (25%), musculoskeletal pain (43%)[Ref]

Ocular

Very common (10% or more): Dry eye (25%)

Common (1% to 10%): Retinal pigment epithelial detachment (RPED)[Ref]

Other

Very common (10% or more): Fatigue (37%), decreased weight (18%)[Ref]

Genitourinary

Very common (10% or more): Urinary tract infection (23%)[Ref]

Nervous system

Very common (10% or more): Dysgeusia (25%)[Ref]

References

1. Product Information. Lytgobi (futibatinib). Taiho Oncology, Inc. 2022;1.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.